These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 17632164)

  • 1. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
    Nickel JC; Roehrborn CG; O'leary MP; Bostwick DG; Somerville MC; Rittmaster RS
    J Urol; 2007 Sep; 178(3 Pt 1):896-900; discussion 900-1. PubMed ID: 17632164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.
    Nickel JC; Roehrborn C; Montorsi F; Wilson TH; Rittmaster RS
    J Urol; 2011 Oct; 186(4):1313-8. PubMed ID: 21849186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial.
    Nickel JC; Downey J; Johnston B; Clark J;
    J Urol; 2001 May; 165(5):1539-44. PubMed ID: 11342913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function.
    Marszalek M; Wehrberger C; Hochreiter W; Temml C; Madersbacher S
    J Urol; 2007 May; 177(5):1815-9. PubMed ID: 17437827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index.
    Nickel JC; Downey J; Hunter D; Clark J
    J Urol; 2001 Mar; 165(3):842-5. PubMed ID: 11176483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
    Cheah PY; Liong ML; Yuen KH; Teh CL; Khor T; Yang JR; Yap HW; Krieger JN
    J Urol; 2003 Feb; 169(2):592-6. PubMed ID: 12544314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study.
    Tripp DA; Curtis Nickel J; Landis JR; Wang YL; Knauss JS;
    BJU Int; 2004 Dec; 94(9):1279-82. PubMed ID: 15610105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of prostatitis-like symptoms in a managed care population.
    Clemens JQ; Meenan RT; O'Keeffe-Rosetti MC; Gao SY; Brown SO; Calhoun EA
    J Urol; 2006 Aug; 176(2):593-6; discussion 596. PubMed ID: 16813895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic prostatitis/chronic pelvic pain syndrome: symptoms are aggravated by cold and become less distressing with age and time.
    Hedelin H; Jonsson K
    Scand J Urol Nephrol; 2007; 41(6):516-20. PubMed ID: 17853027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial.
    Nickel JC; Narayan P; McKay J; Doyle C
    J Urol; 2004 Apr; 171(4):1594-7. PubMed ID: 15017228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study.
    Schaeffer AJ; Landis JR; Knauss JS; Propert KJ; Alexander RB; Litwin MS; Nickel JC; O'Leary MP; Nadler RB; Pontari MA; Shoskes DA; Zeitlin SI; Fowler JE; Mazurick CA; Kishel L; Kusek JW; Nyberg LM;
    J Urol; 2002 Aug; 168(2):593-8. PubMed ID: 12131316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training.
    Anderson RU; Wise D; Sawyer T; Chan CA
    J Urol; 2006 Oct; 176(4 Pt 1):1534-8; discussion 1538-9. PubMed ID: 16952676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.